東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Relevant drug to drug interactions b...

The University of Texas School of Public Health., Epidemiology & Disease Control.

FindBook

Google Book

Amazon

博客來

Relevant drug to drug interactions between itraconazole and non-nucleoside reverse transcriptase inhibitors in HIV-infected patients on maintenance therapy for disseminated histoplasmosis.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Relevant drug to drug interactions between itraconazole and non-nucleoside reverse transcriptase inhibitors in HIV-infected patients on maintenance therapy for disseminated histoplasmosis./
作者:	Evans, Richard T.
面頁冊數:	54 p.
附註:	Adviser: Jan M.H. Risser.
Contained By:	Masters Abstracts International47-01.
標題:	Health Sciences, General. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=1454369
ISBN:	9780549662587

Relevant drug to drug interactions between itraconazole and non-nucleoside reverse transcriptase inhibitors in HIV-infected patients on maintenance therapy for disseminated histoplasmosis.
Evans, Richard T.

Relevant drug to drug interactions between itraconazole and non-nucleoside reverse transcriptase inhibitors in HIV-infected patients on maintenance therapy for disseminated histoplasmosis. - 54 p.

Adviser: Jan M.H. Risser.

Thesis (M.S.)--The University of Texas School of Public Health, 2008.

Design. Retrospective cohort.

ISBN: 9780549662587Subjects--Topical Terms:

1017817
Health Sciences, General.

Relevant drug to drug interactions between itraconazole and non-nucleoside reverse transcriptase inhibitors in HIV-infected patients on maintenance therapy for disseminated histoplasmosis.
LDR:03235nam 2200373 a 45 001 861417
005 20100719
008 100719s2008 ||||||||||||||||| ||eng d
020 $a 9780549662587
035 $a (UMI)AAI1454369
035 $a AAI1454369
040 $a UMI $c UMI
100 1 $a Evans, Richard T. $3 1029123
245 1 0 $a Relevant drug to drug interactions between itraconazole and non-nucleoside reverse transcriptase inhibitors in HIV-infected patients on maintenance therapy for disseminated histoplasmosis.
300 $a 54 p.
500 $a Adviser: Jan M.H. Risser.
500 $a Source: Masters Abstracts International, Volume: 47-01, page: 0342.
502 $a Thesis (M.S.)--The University of Texas School of Public Health, 2008.
520 $a Design. Retrospective cohort.
520 $a Objective. Itraconazole is recommended life-long for preventing relapse of disseminated histoplasmosis in HIV-infected patients. I sought to determine if serum itraconazole levels are affected by the type of Highly Active Anti-Retroviral Therapy (NNRTI or PI) being taken concomitantly to treat HIV.
520 $a Methods. De-identified data were used from an IRB-approved parent study which identified patients on HAART and maintenance itraconazole for confirmed disseminated histoplasmosis between January 2003 and December 2006. Available itraconazole blood levels were abstracted as well as medications taken by each patient at the time of the blood tests. Mean itraconazole levels were compared using the student's t-test.
520 $a Results. 11 patients met study criteria. Patient characteristics were: median age 36, 91% men, 18% white, 18% black, 55% Hispanic and 9% Asians, median CD4 cell count 120 cells/mm3. 14 blood levels were available for analysis---8 on PI, 4 on NNRTI and 2 on both. 8/8 itraconazole levels obtained while taking concomitant PI were therapeutic (>0.4 mug/mL) in contrast to 0/4 obtained while taking NNRTI. Two patients switched from NNRTI to PI and reached therapeutic levels. Mean levels on NNRTI (0.05 mug/mL, s.d. 0.0) and on PI (2.45 mug/mL, s.d. 0.21) for these two patients were compared via a paired t-test (t = 16.00, d.f. = 1, P = 0.04). Remaining patient levels were compared using an unpaired t-test. Mean itraconazole on concomitant PI (n = 6) was 1.37 mug/mL (s.d. 0.74), while the mean on concomitant NNRTI was 0.05 mug/mL (s.d. 0.0), t = 2.39, d.f. = 6, P = 0.05.
520 $a Conclusions. Co-administration of NNRTI and itraconazole results in significant decreases in itraconazole blood levels, likely by inducing the CYP3A4 enzyme system. Itraconazole drug levels should be monitored in patients on concomitant NNRTI. PI-based HAART may be preferred over NNRTI-based HAART when using itraconazole to treat HIV-infected patients with disseminated histoplasmosis.
590 $a School code: 0219.
650 4 $a Health Sciences, General. $3 1017817
650 4 $a Health Sciences, Pharmacology. $3 1017717
650 4 $a Health Sciences, Public Health. $3 1017659
690 $a 0419
690 $a 0566
690 $a 0573
710 2 $a The University of Texas School of Public Health. $b Epidemiology & Disease Control. $3 1019542
773 0 $t Masters Abstracts International $g 47-01.
790 $a 0219
790 1 0 $a Andrade, Roberto A. $e committee member
790 1 0 $a Dunn, J. Kay $e committee member
790 1 0 $a Risser, Jan M.H., $e advisor
790 1 0 $a Ross, Michael W. $e committee member
791 $a M.S.
792 $a 2008
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=1454369